Whether you’re watching the Super Bowl this year as a football fan or a Swiftie, why not make Taylor Swift’s favorite ...

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of ...

You've heard of the Kentucky Derby's famous mint julep and the Kentucky Oaks Lily, but what about The Woodford Reserve Spire?

Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q1 2025 earnings at $6.80 EPS and FY2025 earnings at $33.55 EPS. Get Regeneron Pharmaceuticals alerts: Other equities ...

Regeneron’s cocktail, REGN-COV2 and Eli Lilly’s bamlanivimab have emergency approvals from the FDA and AstraZeneca has begun clinical development of its rival antibody cocktail last month.

The Cosmopolitan is back in a big way. At a new Manhattan club, a floral spritz and other judicious additions give the ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.